Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

People hospitalized after stroke on a weekend more likely to die: Study

People admitted to the hospital on a weekend after a stroke are more likely to die compared to people admitted on a weekday, regardless of the severity of the stroke they experience, according to new research published in the November 2, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

3 Nov 2010

Study reveals a potential target for treating brain trauma

Brain damage continues to develop and evolve for months after a traumatic brain injury (TBI), revealing a potential target for treatments to improve brain trauma, new research led by the University of Melbourne, Australia has found.

3 Nov 2010

Dementia patients should receive high-quality palliative care

The system for hospice admissions for patients with advanced dementia, which is a terminal illness, should be guided by patient and family preference for comfort, not estimated life expectancy, says a new study published in the Nov. 3 Journal of the American Medical Association by the Institute for Aging Research at Hebrew SeniorLife, an affiliate of Harvard Medical School.

3 Nov 2010

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

A team of scientists from Japan and the University of California, San Diego School of Medicine have created a new mouse model that confirms that mutations of a protein called beta-synuclein promote neurodegeneration. The discovery creates a potential new target for developing treatments of diseases like Parkinson's and Alzheimer's.

3 Nov 2010

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP program recognized Quanterix's Single Molecule Array (SiMoA™) platform as a promising advance that will improve diagnosis and treatment of disease while reducing healthcare costs.

3 Nov 2010

Drinking beet juice increases blood flow to the brain

Researchers for the first time have shown that drinking beet juice can increase blood flow to the brain in older adults - a finding that could hold great potential for combating the progression of dementia.

3 Nov 2010

Study finds DHA supplementation does not reduce risk of AD

Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.

3 Nov 2010

Medicare Roundup: Courts widen coverage of skilled care; experts give enrollment advice

Two federal courts have ruled that the Obama administration is using overly strict standards to determine whether older Americans are entitled to Medicare coverage of skilled nursing home care and home health care.

3 Nov 2010

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

Ligand Pharmaceuticals Incorporated today announced it has been awarded $1,955,834 in immediately available funds from the U.S. government under HR: 3590 - Patient Protection and Affordable Care Act. The award comprises separate payments of approximately $245,000 for each of eight drug development programs at Ligand.

2 Nov 2010

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).

2 Nov 2010

Molecular imaging technique pinpoints changes that take place in injured brain

Results from a study published in the November issue of The Journal of Nuclear Medicine (JNM) show that powerful imaging techniques positron emission tomography (PET) fused with magnetic resonance imaging (MRI) are helping researchers better understand the long-term functional and structural changes that take place after traumatic brain injury (TBI).

2 Nov 2010

ArcticDx develops test to determine inherited risk for AMD

Established in 2007 and based in Toronto, ArcticDx has developed a test, Macula Risk-, the first of its kind and specifically designed to determine one's inherited risk for age-related macular degeneration (AMD), the most common form of acquired blindness in the developed world, affecting over 10% of individuals. ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.

2 Nov 2010

Arthritis drugs also prevent post-operative cognitive decline: Study

Anti-inflammatory drugs currently used to treat diseases such as rheumatoid arthritis may also help prevent cognitive problems after surgery, according to a new study by researchers at Imperial College London and University of California, San Francisco (UCSF).

2 Nov 2010

NICE to lose its power to ban life saving drugs

Ministers have finally clarified that patients would not be denied life-extending drugs just because the NHS rationing body decides they are too expensive. National Institute for Health and Clinical Excellence (NICE) the drug watchdog in the UK will be stripped of its powers to stop drugs being available on the NHS due to price. The arbitrary limit on the cost of new drugs – around £30,000 per year of extended high-quality life – will be scrapped from 2014.

1 Nov 2010

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

As the champagne corks are popping this New Year's Eve, the first American Baby Boomers will turn age 65. Members of the demographic bulge that transformed American politics and culture are expected to usher in yet another momentous change a huge increase in the number of Alzheimer's disease patients.

1 Nov 2010

2010 Mid-Atlantic Bio a great kick-off for hosting 2011 BIO International Convention

The 2010 Mid-Atlantic Bio today completed another successful conference hosting 728 registrants from 22 states and 4 countries, with more than 400 companies and 50 qualified investors participating. Dedicated to promoting the biotechnology industry in the Mid-Atlantic region, the conference is hosted collectively by the region's most influential bioscience and investor associations, the Mid-Atlantic Venture Association (MAVA), the Tech Council of Maryland/MdBio (MdBio) and the Virginia Biotechnology Association (VaBIO).

30 Oct 2010

FDA approves NUEDEXTA capsules for pseudobulbar affect

AVANIR Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.

30 Oct 2010

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it has created the Interlaken Leadership Awards. This global awards program will provide monetary grants to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders.

29 Oct 2010

EUCOMMTOOLS partners to receive 12 million euros research funding from European Commission

The findings will contribute to a better understanding of the pathogenesis of widespread diseases such as Alzheimer's, depression, diabetes, chronic lung diseases or cancer. Over the next five years, the eight EUCOMMTOOLS partners, coordinated by Professor Wolfgang Wurst of Helmholtz Zentrum M-nchen, will receive research funding amounting to approximately 12 million euros from the European Commission.

29 Oct 2010

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

People hospitalized after stroke on a weekend more likely to die: Study

Study reveals a potential target for treating brain trauma

Dementia patients should receive high-quality palliative care

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Drinking beet juice increases blood flow to the brain

Study finds DHA supplementation does not reduce risk of AD

Medicare Roundup: Courts widen coverage of skilled care; experts give enrollment advice

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Molecular imaging technique pinpoints changes that take place in injured brain

ArcticDx develops test to determine inherited risk for AMD

Arthritis drugs also prevent post-operative cognitive decline: Study

NICE to lose its power to ban life saving drugs

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

2010 Mid-Atlantic Bio a great kick-off for hosting 2011 BIO International Convention

FDA approves NUEDEXTA capsules for pseudobulbar affect

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

EUCOMMTOOLS partners to receive 12 million euros research funding from European Commission

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in